Connor, Clark & Lunn Investment Management Ltd. Kal Vista Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.8 Billion
- Q1 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 68,205 shares of KALV stock, worth $785,039. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68,205
Previous 110,922
38.51%
Holding current value
$785,039
Previous $1.36 Million
40.5%
% of portfolio
0.0%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding KALV
# of Institutions
129Shares Held
46.5MCall Options Held
113KPut Options Held
72K-
Vr Adviser, LLC New York, NY6.25MShares$71.9 Million6.36% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.19MShares$48.2 Million2.13% of portfolio
-
Tang Capital Management LLC San Diego, CA4.13MShares$47.5 Million5.96% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.69MShares$42.4 Million2.3% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.58MShares$29.6 Million0.06% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $283M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...